Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia.
Yoshimi
A
A
Mohamed
M
M
Bierings
M
M
Urban
C
C
Korthof
E
E
Zecca
M
M
Sykora
K-W
KW
Duffner
U
U
Trebo
M
M
Matthes-Martin
S
S
Sedlacek
P
P
Klingebiel
T
T
Lang
P
P
Führer
M
M
Claviez
A
A
Wössmann
W
W
Pession
A
A
Arvidson
J
J
O'Marcaigh
A S
AS
van den Heuvel-Eibrink
M M
MM
Starý
J
J
Hasle
H
H
Nöllke
P
P
Locatelli
F
F
Niemeyer
C M
CM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000601:surgery*; D015477:Leukemia, Myelomonocytic, Chronic; D008297:Male; D011183:Postoperative Complications / Q000401:mortality; D012008:Recurrence; D012074:Remission Induction; D012086:Reoperation; D016879:Salvage Therapy; D013156:Splenectomy; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous / Q000706:statistics & numerical data*; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000009:adverse effects
D002066:Busulfan